Leniolisib granted orphan drug designation by European Commission for treatment activated phosphoinositide 3-kinase delta syndrome (APDS)

APDS is an ultra-rare, genetic, primary immunodeficiency disease characterised by increased susceptibility to recurrent and severe infections, chronic benign lymphoproliferation and autoimmune disease. Leniolisib is a small molecule PI3Kδ inhibitor with immunomodulating effects.

Source:

PharmaTimes